ridvan_celik
Agility therapy (NASDAQ:AGRX) speak it expects full-year 2023 net sales to be between $25 million and $30 million.
Twirla factory sales for Q4 2022 are expected to be around 42.2k cycles, +30% Q/Q. the company said total cycles of ~42.6K would be an all-time high for factory sales for a quarter.
Twirla factory sales for the full year 2022 are expected to be ~113.6K total cycles, +232% Y/Y.
“Our first commercial product, Twirla, demonstrated rapid growth in the second half of 2022 and now we are excited to enter 2023 with strong momentum,” said Al Altomari, President and CEO of Agile said. “We expect that trend to continue throughout 2023, even as we plan to keep operating costs at the same level as the second half of 2022.”
Agile notes that based on its commercial plan for 2023, the company expects an increased revenue contribution from the Twirla business in 2023, and full-year net sales will be between 25 million and 30 million. dollars. The company plans to keep operating costs at the same level as the second half of 2022.
AGRX +6.99% up to $0.29 premarket on January 9
